LIBERVANT Drug Patent Profile
✉ Email this page to a colleague
When do Libervant patents expire, and when can generic versions of Libervant launch?
Libervant is a drug marketed by Aquestive and is included in one NDA. There is one patent protecting this drug.
This drug has twenty patent family members in eight countries.
The generic ingredient in LIBERVANT is diazepam. There are eight drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the diazepam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Libervant
A generic version of LIBERVANT was approved as diazepam by MYLAN on September 4th, 1985.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LIBERVANT?
- What are the global sales for LIBERVANT?
- What is Average Wholesale Price for LIBERVANT?
Summary for LIBERVANT
International Patents: | 20 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Patent Applications: | 4,156 |
What excipients (inactive ingredients) are in LIBERVANT? | LIBERVANT excipients list |
DailyMed Link: | LIBERVANT at DailyMed |
Pharmacology for LIBERVANT
Drug Class | Benzodiazepine |
US Patents and Regulatory Information for LIBERVANT
LIBERVANT is protected by one US patents and one FDA Regulatory Exclusivity.
Patents protecting LIBERVANT
Pharmaceutical compositions with enhanced permeation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting LIBERVANT
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aquestive | LIBERVANT | diazepam | FILM;BUCCAL | 218623-001 | Apr 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Aquestive | LIBERVANT | diazepam | FILM;BUCCAL | 218623-004 | Apr 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Aquestive | LIBERVANT | diazepam | FILM;BUCCAL | 218623-002 | Apr 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Aquestive | LIBERVANT | diazepam | FILM;BUCCAL | 218623-004 | Apr 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LIBERVANT
See the table below for patents covering LIBERVANT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | 112020005967 | composições farmacêuticas com permeação realçada | ⤷ Sign Up |
Canada | 3022797 | COMPOSITIONS PHARMACEUTIQUES A PERMEATION AMELIOREE (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION) | ⤷ Sign Up |
Japan | 2024012484 | 増強された透過を有する医薬組成物 | ⤷ Sign Up |
China | 111132670 | 具有增强的渗透的药物组合物 (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |